Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Carbiotix
Lund (historically/founder university), Skåne, Swedencarbiotix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Carbiotix’s second-generation soluble fiber CarbiAXOS has achieved regulatory approval for cosmetic uses, promising results in a Metformin study, and is being commercially produced for food, feed, and possible future therapeutic uses. The LinkGut platform has been validated in a 300-person study for microbiome diagnostics[1].
- Therapeutic areas
- Metabolic DisordersGastroenterologyDermatology
- Modalities
- Microbial therapyLive biotherapeutic product therapyDietary fiber productSmall molecule (related to prebiotic fiber derivatives)
- Industry
- Molecular Diagnostics
02
Partnerships
Collaborations with functional food and probiotics companies (individual partners not explicitly named)[1]
Beyond the preview
Go deeper on Carbiotix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carbiotix.